The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study

Background: Aripiprazole once-monthly 400 mg (AOM 400), an atypical long-acting injectable antipsychotic, has demonstrated efficacy and safety in maintenance treatment of bipolar I disorder (BP-I). We further assess safety and tolerability and characterize adverse events (AEs) across the duration of...

Full description

Bibliographic Details
Main Authors: Amatniek, J. (Author), Calabrese, J.R (Author), Carson, W.H (Author), Cox, K. (Author), Hertel, P. (Author), Jin, N. (Author), Johnson, B. (Author), McQuade, R.D (Author), Nyilas, M. (Author), Perry, P.P (Author), Sanchez, R. (Author), Such, P. (Author)
Format: Article
Language:English
Published: Elsevier B.V. 2018
Subjects:
Online Access:View Fulltext in Publisher